Dai, Min <br/><br/>
Tumor Regression and Cure Depends on Sustained Th1 Responses.  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)  10 2018 
 - 369-378 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1537-4513 
<br/><br/><label>Standard No.: </label>10.1097/CJI.0000000000000231  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antigens, CD19--immunology<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Cisplatin--therapeutic use<br/>Disease Models, Animal<br/>Female<br/>Lung Neoplasms--drug therapy<br/>Mice, Inbred C3H<br/>Mice, Inbred C57BL<br/>Neoplasm Recurrence, Local<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Th1 Cells--drug effects<br/>Th2 Cells--drug effects<br/>Tumor Microenvironment--drug effects<br/>Tumor Necrosis Factor Receptor Superfamily, Member 9--antagonists & inhibitors